Recent approval

In December 2017, the European Commission (or EC) approved Roche’s (RHHBY) Alecensa (alectinib) as a monotherapy for the first-line treatment of individuals with anaplastic lymphoma kinase ALK-positive advanced NSCLC (non-small cell lung cancer). In 1Q17, 2Q17, and 3Q17, Roche’s Alecensa reported revenues of 68 million Swiss francs, 80 million Swiss francs, and 96 million Swiss francs, respectively.

Approval of Alecensa in Europe Could Boost Roche’s Revenue Growth

ALEX trial

The EC approved Alecensa based on the results of the phase three ALEX trial. In the trial, Alecensa demonstrated a significant reduction in the risk of the disease worsening or death by 53% compared to crizotinib. In the phase three ALEX trial, Alecensa also demonstrated a reduction in the risk of tumors spreading to the brain or central nervous system by 84% compared to crizotinib.

During the trial, patients on Alecensa demonstrated median progression-free survival of 25.7 months, as evaluated by the Independent Review Committee compared to 10.4 months for patients on crizotinib.

Alecensa’s safety profile remained consistent with the prior studies and compared positively to Pfizer’s (PFE) Xalkori (crizotinib).

The EC converted the conditional marketing authorization of Alecensa in crizotinib failure to a complete standard marketing authorization. In November 2017, Alecensa received approval from the US FDA (Food and Drug Administration), Japan, and Turkey as a first-line treatment for individuals with ALK-positive NSCLC.

Alecensa’s peers include Takeda Pharmaceuticals’ (TKPYY) Alunbrig, Novartis’s (NVS) Zykadia, and Pfizer’s (PFE) Xalkori. The growth in sales of Roche’s Alecensa and Novartis’s Zykadia could boost the Vanguard FTSE All-World ex-US ETF (VEU). Roche and Novartis make up about ~0.69% and 0.79% of VEU’s total portfolio holdings, respectively.

Latest articles

This year, Pfizer (PFE) stock has fallen 0.34% and Bristol-Myers Squibb (BMY) stock has fallen 6.48%. Both companies are focused on strengthening their position in the high-growth oncology and immunology markets. Let's take a closer look at each.

Walt Disney’s (DIS) latest movie, Toy Story 4, has reportedly broken records in the opening weekend with $118 million in sales. However, the opening weekend collection was behind analysts’ expectations of at least $150 million in the first weekend.

24 Jun

Will Home Depot’s Upward Momentum to Continue?

WRITTEN BY Rajiv Nanjapla

As of June 21, Home Depot (HD) was trading at $209.39, which implies a rise of 9.7% since the announcement of its first-quarter earnings on May 21. Also, the company was trading at a premium of 32.4% from its 52-week low of $158.09 and a discount of 2.8% from its 52-week high of $215.43.

On June 21, Aurora Cannabis (ACB) made an announcement that indicated that it will move towards higher margin vape products. In addition, the company also believes concentrates and edibles will command higher margins. In anticipation of this development, the company announced the expansion of its facility to capitalize on growth related to these segments.

Shares of Mondelēz International (MDLZ) are scaling new heights thanks to its stellar gains so far this year. Mondelēz stock is up 38.0% on a YTD (year-to-date) basis, and it closed at $55.25—just a shade lower than its 52-week high of $55.71—on June 21.

24 Jun

How Long Will Facebook's Libra Fuel Bitcoin Rally?

WRITTEN BY Mayur Sontakke, CFA, FRM

Ever since the news about Facebook’s (FB) cryptocurrency project broke, Bitcoin has rallied on the hope that Facebook’s entry in the space will help make cryptocurrencies mainstream. Facebook’s cryptocurrency will be called Libra and will be governed by an association with 28 founding members across industries.

172.31.59.107